OBJECTIVES: To assess the cost-effectiveness of whether loratadine is combined with spleen aminopeptide oral solution in afflicted child with Adenoidal Hypertrophy(AH) from the perspective of the societal perspective. With a view to guide the rational allocation of health resources in clinical practice.

METHODS: Construction of a Markov model based on data from clinical trials(ChiCTR2200056763) and literature studies to assess the short-term costs and health outputs of loratadine in combination with/without spleen aminopeptide oral solution in afflicted child with AH. Costs include direct medical costs, direct non-medical costs, and indirect costs. Using Quality Adjusted Life Years(QALY) as a health output. Final calculation of the Incremental Cost Effectiveness Ratio(ICER) of the two treatment options. The robustness of the results was verified by single factor sensitivity analysis and probability.

RESULTS: Compared with loratadine alone, the costs of loratadine in combination with spleen aminopeptide oral solution were lower (¥2,038.78 vs. ¥3,029.07), and the efficacy were better (0.8851 QALYs vs. 0.8993 QALYs). ICER were ¥69,609.87 per QALY, less than 1 time of Chinese Gross Domestic Product(GDP) per capita. The result of sensitivity analysis verified that the model was robust.

CONCLUSIONS: From a societal perspective, for afflicted child with AH, loratadine in combination with spleen aminopeptide oral solution has an economic advantage over loratadine monotherapy when the Willing to Pay (WTP) value is 1 time of GDP per capita.